<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/> 
  <meta name="type" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/04/09/2020.04.07.029488.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.04.07.029488v1"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity — opportunity for repurposed chemotherapy of COVID-19 infection"/>
  <meta name="DC.Identifier" content="10.1101/2020.04.07.029488"/>
  <meta name="DC.Date" content="2020-04-09"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="© 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission."/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="There is an urgent requirement for improved treatments of COVID-19 disease. A strategy for chemotherapy is to increase levels of endogenous reactive metabolites — such as reactive oxygen species and arginine-directed glycating agent, methylglyoxal — for selective toxicity to SARS-CoV-2. Sequence analysis of functional domains in the SARS-CoV-2 proteome showed 0.8 fold depletion of cysteine residues and 4.9 fold enrichment of arginine residues, suggesting methylglyoxal modification may inactivate the virus. We discovered the peptide motif for MG modification: 3 – 5-fold enrichment of cationic residues preceding the target arginine. There was 5-fold enrichment of methylglyoxal modification sites in the SARS-CoV-2 proteome, compared to the human host - indicating selective toxicity of methylglyoxal to the virus. We found antitumor drugs, doxorubicin and paclitaxel, increase cellular methylglyoxal to virucidal levels. Taken together, these findings reveal a proteomic vulnerability of SARS-CoV-2 to methylglyoxal modification and provide a rationale for repurposing doxorubicin and paclitaxel for COVID-19 treatment. ### Competing Interest Statement"/>
  <meta name="DC.Contributor" content="Maryam Al-Motawa"/>
  <meta name="DC.Contributor" content="Hafsa Abbas"/>
  <meta name="DC.Contributor" content="Patrick Wijten"/>
  <meta name="DC.Contributor" content="Alberto de la Fuente"/>
  <meta name="DC.Contributor" content="Mingzhan Xue"/>
  <meta name="DC.Contributor" content="Naila Rabbani"/>
  <meta name="DC.Contributor" content="Paul Thornalley"/>
  <meta name="article:published_time" content="2020-04-09"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity — opportunity for repurposed chemotherapy of COVID-19 infection"/>
  <meta name="citation_abstract" lang="en" content="&lt;;p&gt;;There is an urgent requirement for improved treatments of COVID-19 disease. A strategy for chemotherapy is to increase levels of endogenous reactive metabolites — such as reactive oxygen species and arginine-directed glycating agent, methylglyoxal — for selective toxicity to SARS-CoV-2. Sequence analysis of functional domains in the SARS-CoV-2 proteome showed 0.8 fold depletion of cysteine residues and 4.9 fold enrichment of arginine residues, suggesting methylglyoxal modification may inactivate the virus. We discovered the peptide motif for MG modification: 3 – 5-fold enrichment of cationic residues preceding the target arginine. There was 5-fold enrichment of methylglyoxal modification sites in the SARS-CoV-2 proteome, compared to the human host - indicating selective toxicity of methylglyoxal to the virus. We found antitumor drugs, doxorubicin and paclitaxel, increase cellular methylglyoxal to virucidal levels. Taken together, these findings reveal a proteomic vulnerability of SARS-CoV-2 to methylglyoxal modification and provide a rationale for repurposing doxorubicin and paclitaxel for COVID-19 treatment.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.04.07.029488v1"/>
  <meta name="citation_id" content="2020.04.07.029488v1"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.029488v1"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.029488v1.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.029488v1.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/04/09/2020.04.07.029488.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.04.07.029488"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.04.07.029488"/>
  <meta name="citation_author" content="Maryam Al-Motawa"/>
  <meta name="citation_author_institution" content="Hamad Bin Khalifa University;"/>
  <meta name="citation_author_email" content="malmotawa@hbku.edu.qa"/>
  <meta name="citation_author" content="Hafsa Abbas"/>
  <meta name="citation_author_institution" content="University of Warwick;"/>
  <meta name="citation_author_email" content="h.abbas.1@warwick.ac.uk"/>
  <meta name="citation_author" content="Patrick Wijten"/>
  <meta name="citation_author_institution" content="Hamad Bin Khalifa University;"/>
  <meta name="citation_author_email" content="pwijten@hbku.edu.qa"/>
  <meta name="citation_author" content="Alberto de la Fuente"/>
  <meta name="citation_author_institution" content="Hamad Bin Khalifa University;"/>
  <meta name="citation_author_email" content="adelafuente@hbku.edu.qa"/>
  <meta name="citation_author" content="Mingzhan Xue"/>
  <meta name="citation_author_institution" content="Hamad Bin Khalifa University;"/>
  <meta name="citation_author_email" content="mxue@hbku.edu.qa"/>
  <meta name="citation_author" content="Naila Rabbani"/>
  <meta name="citation_author_institution" content="Qatar University"/>
  <meta name="citation_author_email" content="n.rabbani@qu.edu.qa"/>
  <meta name="citation_author" content="Paul Thornalley"/>
  <meta name="citation_author_institution" content="Hamad Bin Khalifa University;"/>
  <meta name="citation_author_email" content="pthornalley@hbku.edu.qa"/>
  <meta name="twitter:title" content="Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity — opportunity for repurposed chemotherapy of COVID-19 infection"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="There is an urgent requirement for improved treatments of COVID-19 disease. A strategy for chemotherapy is to increase levels of endogenous reactive metabolites — such as reactive oxygen species and arginine-directed glycating agent, methylglyoxal — for selective toxicity to SARS-CoV-2. Sequence analysis of functional domains in the SARS-CoV-2 proteome showed 0.8 fold depletion of cysteine residues and 4.9 fold enrichment of arginine residues, suggesting methylglyoxal modification may inactivate the virus. We discovered the peptide motif for MG modification: 3 – 5-fold enrichment of cationic residues preceding the target arginine. There was 5-fold enrichment of methylglyoxal modification sites in the SARS-CoV-2 proteome, compared to the human host - indicating selective toxicity of methylglyoxal to the virus. We found antitumor drugs, doxorubicin and paclitaxel, increase cellular methylglyoxal to virucidal levels. Taken together, these findings reveal a proteomic vulnerability of SARS-CoV-2 to methylglyoxal modification and provide a rationale for repurposing doxorubicin and paclitaxel for COVID-19 treatment. ### Competing Interest Statement"/>
  <meta name="og-title" property="og:title" content="Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity — opportunity for repurposed chemotherapy of COVID-19 infection"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.029488v1"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="There is an urgent requirement for improved treatments of COVID-19 disease. A strategy for chemotherapy is to increase levels of endogenous reactive metabolites — such as reactive oxygen species and arginine-directed glycating agent, methylglyoxal — for selective toxicity to SARS-CoV-2. Sequence analysis of functional domains in the SARS-CoV-2 proteome showed 0.8 fold depletion of cysteine residues and 4.9 fold enrichment of arginine residues, suggesting methylglyoxal modification may inactivate the virus. We discovered the peptide motif for MG modification: 3 – 5-fold enrichment of cationic residues preceding the target arginine. There was 5-fold enrichment of methylglyoxal modification sites in the SARS-CoV-2 proteome, compared to the human host - indicating selective toxicity of methylglyoxal to the virus. We found antitumor drugs, doxorubicin and paclitaxel, increase cellular methylglyoxal to virucidal levels. Taken together, these findings reveal a proteomic vulnerability of SARS-CoV-2 to methylglyoxal modification and provide a rationale for repurposing doxorubicin and paclitaxel for COVID-19 treatment. ### Competing Interest Statement"/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-04-09"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity — opportunity for repurposed chemotherapy of COVID-19 infection | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1237329 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-category-new-results"> 
  <div class="article abstract-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2>Abstract</h2>
    <p id="p-2">There is an urgent requirement for improved treatments of COVID-19 disease. A strategy for chemotherapy is to increase levels of endogenous reactive metabolites — such as reactive oxygen species and arginine-directed glycating agent, methylglyoxal — for selective toxicity to SARS-CoV-2. Sequence analysis of functional domains in the SARS-CoV-2 proteome showed 0.8 fold depletion of cysteine residues and 4.9 fold enrichment of arginine residues, suggesting methylglyoxal modification may inactivate the virus. We discovered the peptide motif for MG modification: 3 – 5-fold enrichment of cationic residues preceding the target arginine. There was 5-fold enrichment of methylglyoxal modification sites in the SARS-CoV-2 proteome, compared to the human host - indicating selective toxicity of methylglyoxal to the virus. We found antitumor drugs, doxorubicin and paclitaxel, increase cellular methylglyoxal to virucidal levels. Taken together, these findings reveal a proteomic vulnerability of SARS-CoV-2 to methylglyoxal modification and provide a rationale for repurposing doxorubicin and paclitaxel for COVID-19 treatment.</p>
   </div>
   <h3>Competing Interest Statement</h3>
   <p id="p-3"/>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
